10 results
The aim of this study is to test the hypothesis that a combination of optimized intravenous pain therapy and continuous sciatic nerve block decreases the point prevalence of phantom limb pain 12 months after transtibial amputation for peripheral…
The primary objective of this trial is to determine whether different types of anaesthesia [regional versus general] given to infants undergoing inguinal hernia repair result in equivalent neurodevelopmental outcomes. Secondary objectives are to…
Primary objective: To demonstrate superior renal allograft function in de novo renal transplant recipients after early CNI to everolimus conversion assessed by Glomerular Filtration Rate (eGFR) estimated by the Modification of Diet in Renal Disease…
The study-objective of this prospective randomised dubbelblind clinical trial is to demonstrate superior anaesthesia with infiltration of the portals with 20cc of bupivacaine compared tot not giving portal anaesthesia.
The study-objective of this prospective randomised dubbelblind clinical trial is to demonstrate superior anaesthesia with infiltration of the portals with 10cc of bupivacaine compared tot not giving portal anaesthesia.
Primary objective:To evaluate the postoperative opioid consumption and pain after laparoscopic bariatric surgery. Our hypothesis is that less opioids will be consumed by patients in the group receiving local anesthetics compared to normal saline.…
To improve response rate of primary treatment of extensive chronic GvHD with the addition of MPA to the reference treatment CsA+PDN (comparator)Primary ObjectiveTo improve remission rates with cyclosporine A+ prednisone + Myfortic® (CsA+PDN+MPA)…
Primary objectivesThe primary objective of the study is demonstrate that at least one of the sotrastaurin treatment arms is non-inferior to the active control regimen myfortic + tacrolimus with respect to composite efficacy failure (treated BPAR of…
This study is designed to demonstrate equal therapeutic effect of Myfortic® as compared to MMF in this patient group, thus improving therapeutic efficacy.
Objectives: - to increase the proportion of patients with non-severe GVHD within 180 days post-allo-SCT - to reduce the progression rate - to improve the progression free survival- to asses the impact on the quality of life using a time restricted…